EN DE
Watch Vivanza Biosciences Ltd for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Vivanza Biosciences Ltd (VIVANZA) fair value: what the stock is really worth

As of Nov 19, 2026: fair value (intrinsic value) of Vivanza Biosciences Ltd stock ₹1.41, price ₹1.44, that is 2.1% below the price, quality 52 out of 100. Rating: fairly valued. Calculated from audited financials with 15 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare IN · ISIN INE984E01035

VB Vivanza Biosciences Ltd logo Thin data Nov 19, 2026

Vivanza Biosciences Ltd

VIVANZA · BSE

Solid company, but the stock is already about fairly priced and falling price: meets 1 of 3 rules.

Follow free in the weekly email
Low debt 
Profit last quarter +100% vs. a year ago. 
Fair value ₹1.41 · Fairly valued 
Quality 52/100 
Mixed Growth (revenue 5y +63.6 %/yr in INR) 
Thin margins · 0.4% net margin (TTM) 
Mixed vs. peers (7/12) 
Changed on Nov 2: ₹1.68 → ₹1.41 
Falling price (downtrend) 
Negative free cash flow 
Narrow moat 25/100
Thin data 
⚠ Thinly traded
Watch Vivanza Biosciences Ltd for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹21.00 ₹1.25 Fair Value ₹1.41 Oct 2016 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 19, 2026.

How to read this chart

60‑month range ₹1.25 – ₹21.00 · fair‑value band ₹1.09 – ₹1.95 · the ₹1.44 price screens above the ₹1.41 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 19, 2026.

Follow Vivanza Biosciences in your weekly email

Every Wednesday you see whether Vivanza Biosciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Vivanza Biosciences Limited engages in the research and development, manufacturing, and the distribution of pharmaceutical products in India. It offers latex surgical and examination, and latex free gloves, as well as other surgical products.

Show moreShow less

The company was incorporated in 1982 and is based in Ahmedabad, India.

Stock analysis

Vivanza Biosciences Ltd (VIVANZA) currently trades at ₹1.44, while our model-based Fair Value estimate is ₹1.41, so the stock looks roughly fairly valued today (gap 2.1%).

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of ₹1.77 per share, and 5 of the 14 models we run sit above the ₹1.44 price.

Bear case: the Asset-Based group reads lowest at ₹0.3300, and 9 of the 14 models stay below the price. Data coverage for this calculation is low.

Scenario range: ₹1.09 (bear) to ₹1.95 (bull), the price of ₹1.44 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Vivanza Biosciences Ltd reported revenue of ₹1.2B in FY2025 versus ₹104M in FY2021, a compound +82.7%/yr. Reported net income was ₹3.9M in FY2025, compounding +4.3%/yr from FY2021.

Key figures

Market cap ₹57.6M (≈ $616K) Micro · P/E ratio 12.0 · P/S ratio 0.05 · EPS (TTM) ₹0.1200 · Net margin 0.4% · Return on equity 9.5% · Return on assets (EBIT) 1.7% (5-year average) · Operating margin 3.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 25 out of 100 (medium confidence).

What moves the price

The share trades about 40% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −2%, VIVANZA screens cheaper than that median.

Fair Value models

Bear ₹1.09 Fair Value ₹1.41 Bull ₹1.95
Price ₹1.44 · Downside -2.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 11 months old). Earnings retained since then (₹0.1062 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Owner Earnings ₹0.6600 ₹1.18 ₹1.95 74
EPV ₹1.09 ₹1.27 ₹1.42 74
ROIC Compounder ₹1.09 ₹1.41 ₹1.81 72
All 15 models by family
DCF Models
Owner Earnings ₹0.6600 ₹1.18 ₹1.95 74
Earnings-Based
Graham-Dodd ₹0.6700 ₹2.78 ₹3.79 64
Lynch FV ₹0.7000 ₹1.00 ₹1.30 61
PEG = 1.0 ₹0.7000 ₹1.00 ₹1.30 57
EPV ₹1.09 ₹1.27 ₹1.42 74
Multiples
P/E Multiple ₹1.63 ₹2.17 ₹2.71 63
P/S Multiple ₹1.26 ₹1.68 ₹2.10 58
P/B Multiple ₹2.30 ₹3.06 ₹3.83 55
EV/EBIT n/a ₹0.4900 ₹1.25 61
EV/EBITDA n/a ₹0.0300 >₹0.1200 62
EV/Revenue n/a n/a ₹0.4700 50
Asset-Based
NCAV (Graham) ₹0.2200 ₹0.3300 ₹0.4100 55
Economic Profit
Residual Income ₹0.8800 ₹0.9400 ₹1.06 71
ROIC Compounder ₹1.09 ₹1.41 ₹1.81 72
Growth Earnings
Growth-Adj P/E ₹1.24 ₹1.77 ₹2.30 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 52/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 39
How much profit the company makes from its sales and capital
Quality Growth 80
Are margins and returns getting better?
Cashflow 8
Do the profits arrive as real cash?
Financial strength 26
Debt, balance sheet and risk of trouble
Investment 96
Does it invest with discipline instead of growing at any price?
Low Volatility 55
How calm the share price moves, does not count
Price momentum 14
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 3
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 50/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+86.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+63.6%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+47.7%
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+14.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+14.1%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.1% → 1%

Watch VIVANZA, get fair value alerts →

Compare Vivanza Biosciences Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 608 stocks

Beats the industry median on 7/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 52 · Below median
Fair Value upside −2.1% · Above median
Profitability
Return on equity (12 months) 9.5% · Above median
Return on assets 1.8% · Below median
Net margin (12 months) 0.4% · Below median
Operating margin (12 months) 3.0% · Below median
Growth and dividend
Revenue growth (quarter YoY) 7.9% · Above median
Balance sheet
Debt / equity 0.20× · Above median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 12.0× · Cheapest 25%
P/B 1.32× · Cheaper than median
P/S (12 months) 0.05× · Cheapest 25%
EV/EBITDA 6.8× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)31 · sector 20
FUTURE (revenue growth)40 · sector 29
PAST (return on equity)38 · sector 26
HEALTH (low debt)90 · sector 96
DIVIDEND (yield)0 · sector 33

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $85.57 $113.53 +33% vs VIVANZA
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥46.88 ¥52.43 +12% vs VIVANZA
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,900 ₹1,983 +4% vs VIVANZA
Haleon plc HLN $9.08 $8.47 −7% vs VIVANZA
Merck KGaA MRK €148.40 €108.83 −27% vs VIVANZA
Galderma Group GALD CHF 184.70 CHF 112.46 −39% vs VIVANZA
Takeda Pharmaceutical Company TAK $21.27 $11.23 −47% vs VIVANZA
Sandoz Group SDZ CHF 81.24 CHF 41.06 −49% vs VIVANZA
Teva Pharmaceutical Industries Limited TEVA $42.23 $20.74 −51% vs VIVANZA
Divi's Laboratories Limited DIVISLAB ₹11,178 ₹1,567 −86% vs VIVANZA

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Vivanza Biosciences Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Vivanza Biosciences Ltd Fair Value". https://www.fairvalue-calculator.com/stock/VIVANZA

Frequently asked questions

Is Vivanza Biosciences Ltd (VIVANZA) overvalued or undervalued?
As of Nov 19, 2026, our model estimates a fair value of ₹1.41 versus a price of ₹1.44, about 2% lower (fairly valued).
What is the fair value of VIVANZA?
Our model-based fair value for Vivanza Biosciences Ltd is ₹1.41 (as of Nov 19, 2026), built from audited fundamentals. The current price: ₹1.44.
What is the quality score of VIVANZA?
Vivanza Biosciences Ltd has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Vivanza Biosciences Ltd (VIVANZA)?
We do not set a price target; the yardstick is the fair value of ₹1.41 (as of Nov 19, 2026) from 15 valuation models. Cautious scenario ₹1.09, optimistic scenario ₹1.95. It is a calculation from audited fundamentals, not an analyst target.
What is the Vivanza Biosciences Ltd stock forecast for 2026?
Our models put fair value at ₹1.41, about 2% lower versus a price of ₹1.44 (fairly valued). Cautious scenario ₹1.09, optimistic scenario ₹1.95. The calculation is refreshed regularly with new filings.
What is the revenue of Vivanza Biosciences Ltd (VIVANZA)?
Vivanza Biosciences Ltd reported trailing-twelve-month revenue of about ₹1.2B (latest available figure, as of Nov 19, 2026).
What is the intrinsic value of Vivanza Biosciences Ltd (VIVANZA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Vivanza Biosciences Ltd it is ₹1.41 per share (as of Nov 19, 2026), against a price of ₹1.44. It is the blended result of 15 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Vivanza Biosciences Ltd stock overvalued or undervalued in 2026?
As of Nov 19, 2026, VIVANZA trades above its calculated fair value: price ₹1.44, fair value ₹1.41, a gap of about −2% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of VIVANZA?
No. The price is what the market pays today (₹1.44); the fair value is what the company's own numbers justify (₹1.41). For Vivanza Biosciences Ltd the two are ₹0.0300 per share apart. That gap is exactly why we show both numbers side by side.
How much is Vivanza Biosciences Ltd worth?
The market values Vivanza Biosciences Ltd at about ₹57.6M (market capitalisation, as of Nov 19, 2026). Per share that is ₹1.44; our models calculate a fair value of ₹1.41 per share.
What do the bullish and bearish scenarios say about VIVANZA?
Our models span a range for Vivanza Biosciences Ltd: cautious scenario ₹1.09, base ₹1.41, optimistic ₹1.95 per share (as of Nov 19, 2026, price ₹1.44). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of VIVANZA?
Vivanza Biosciences Ltd trades at a price-to-earnings ratio of 12.0 (as of Nov 19, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹1.41 is built from several models across several years. Other multiples: P/B 1.3, P/S 0.0, EV/EBITDA 6.8.
How solid is the balance sheet of Vivanza Biosciences Ltd (VIVANZA)?
Balance-sheet figures for Vivanza Biosciences Ltd (as of Nov 19, 2026): return on equity 9.5%, debt of 0.20 per unit of equity. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is VIVANZA from its 52-week high?
Vivanza Biosciences Ltd trades at ₹1.44, about 40% below its 52-week high of ₹2.40 and 6% above the low of ₹1.36 (as of Nov 19, 2026). Distance from the high says nothing about value: that is what the fair value of ₹1.41 is for.
Which stocks are comparable to Vivanza Biosciences Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Vivanza Biosciences Ltd stock attractive at the current price?
The data as of Nov 19, 2026: price ₹1.44, calculated fair value ₹1.41 (−2%), Quality Score 52/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of VIVANZA calculated?
We run Vivanza Biosciences Ltd through 15 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹1.41 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.0% above its aggregate fair value. Vivanza Biosciences Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Vivanza Biosciences Ltd (VIVANZA)?
The closing price on Nov 19, 2026 was ₹1.44. Our model-based fair value is ₹1.41, about 2% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Vivanza Biosciences Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Vivanza Biosciences Ltd

How large is the market capitalisation of Vivanza Biosciences Ltd (VIVANZA)?
The market capitalisation of Vivanza Biosciences Ltd is ₹57.6M (≈ $616K). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Vivanza Biosciences Ltd (VIVANZA)?
The price-to-sales ratio of Vivanza Biosciences Ltd is 0.05 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Vivanza Biosciences Ltd (VIVANZA)?
Earnings per share at Vivanza Biosciences Ltd are ₹0.1200 (price ÷ EPS = P/E 12.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Vivanza Biosciences Ltd (VIVANZA)?
The net margin of Vivanza Biosciences Ltd is 0.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Vivanza Biosciences Ltd (VIVANZA)?
The return on equity (ROE) of Vivanza Biosciences Ltd is 9.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Vivanza Biosciences Ltd (VIVANZA)?
On an EBIT basis the return on assets of Vivanza Biosciences Ltd is 1.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Vivanza Biosciences Ltd (VIVANZA)?
The operating margin of Vivanza Biosciences Ltd is 3.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Vivanza Biosciences Ltd (VIVANZA)?
Revenue at Vivanza Biosciences Ltd is growing 7.9% versus a year earlier (3y avg +86.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Vivanza Biosciences Ltd (VIVANZA)?
Earnings per share at Vivanza Biosciences Ltd are growing 100% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Vivanza Biosciences Ltd (VIVANZA) generate?
The free cash flow of Vivanza Biosciences Ltd is −₹27.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Vivanza Biosciences Ltd (VIVANZA) carry?
The net debt of Vivanza Biosciences Ltd is ₹101M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Vivanza Biosciences Ltd in the live analysis

One click puts Vivanza Biosciences Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.